,sentence,pubmed_id,content,label,labeler
0,"25 ||| Patients ||| 2.2 ||| Diagnostic criteria for metabolic syndrome included having ≥3 of the 5 National Cholesterol Education Program criteria for metabolic syndrome: triglycerides ≥150 mg/dL, systolic blood pressure ≥130 mmHg and diastolic blood pressure >85 mmHg, fasting blood glucose ≥110 mg/dL, waist circumference >101.6 cm (40 in) for men and >88.9 cm (35 in) for women, and highdensity lipoprotein cholesterol <40 mg/dL for men and <50 mg/dL for women.",20069077,triglycerides ≥150 mg/dL,po.Disease,奉捷
1,"25 ||| Patients ||| 2.2 ||| Diagnostic criteria for metabolic syndrome included having ≥3 of the 5 National Cholesterol Education Program criteria for metabolic syndrome: triglycerides ≥150 mg/dL, systolic blood pressure ≥130 mmHg and diastolic blood pressure >85 mmHg, fasting blood glucose ≥110 mg/dL, waist circumference >101.6 cm (40 in) for men and >88.9 cm (35 in) for women, and highdensity lipoprotein cholesterol <40 mg/dL for men and <50 mg/dL for women.",20069077,waist circumference >101.6 cm (40 in) for men,po.Disease,奉捷
2,"25 ||| Patients ||| 2.2 ||| Diagnostic criteria for metabolic syndrome included having ≥3 of the 5 National Cholesterol Education Program criteria for metabolic syndrome: triglycerides ≥150 mg/dL, systolic blood pressure ≥130 mmHg and diastolic blood pres",20069077,highdensity lipoprotein cholesterol <40 mg/dL for men,po.Disease,奉捷
3,"25 ||| Patients ||| 2.2 ||| Diagnostic criteria for metabolic syndrome included having ≥3 of the 5 National Cholesterol Education Program criteria for metabolic syndrome: triglycerides ≥150 mg/dL, systolic blood pressure ≥130 mmHg and diastolic blood pres",20069077,systolic blood pressure ≥130 mmHg,po.Disease,奉捷
4,"25 ||| Patients ||| 2.2 ||| Diagnostic criteria for metabolic syndrome included having ≥3 of the 5 National Cholesterol Education Program criteria for metabolic syndrome: triglycerides ≥150 mg/dL, systolic blood pressure ≥130 mmHg and diastolic blood pres",20069077, diastolic blood pressure >85 mmHg,po.Disease,奉捷
5,"25 ||| Patients ||| 2.2 ||| Diagnostic criteria for metabolic syndrome included having ≥3 of the 5 National Cholesterol Education Program criteria for metabolic syndrome: triglycerides ≥150 mg/dL, systolic blood pressure ≥130 mmHg and diastolic blood pres",20069077,fasting blood glucose ≥110 mg/dL,po.Disease,奉捷
6,"25 ||| Patients ||| 2.2 ||| Diagnostic criteria for metabolic syndrome included having ≥3 of the 5 National Cholesterol Education Program criteria for metabolic syndrome: triglycerides ≥150 mg/dL, systolic blood pressure ≥130 mmHg and diastolic blood pres",20069077,>88.9 cm (35 in) for women,po.Disease,奉捷
7,"25 ||| Patients ||| 2.2 ||| Diagnostic criteria for metabolic syndrome included having ≥3 of the 5 National Cholesterol Education Program criteria for metabolic syndrome: triglycerides ≥150 mg/dL, systolic blood pressure ≥130 mmHg and diastolic blood pres",20069077,<50 mg/dL for women,po.Disease,奉捷
8,"25 ||| Patients ||| 2.2 ||| Diagnostic criteria for metabolic syndrome included having ≥3 of the 5 National Cholesterol Education Program criteria for metabolic syndrome: triglycerides ≥150 mg/dL, systolic blood pressure ≥130 mmHg and diastolic blood pres",20069077,men,po.Gender,奉捷
9,"25 ||| Patients ||| 2.2 ||| Diagnostic criteria for metabolic syndrome included having ≥3 of the 5 National Cholesterol Education Program criteria for metabolic syndrome: triglycerides ≥150 mg/dL, systolic blood pressure ≥130 mmHg and diastolic blood pres慲据楨䘄牯k䄏灰䤮獮慴汬祔数0ʑࠀ灁⹰慎敭թ硅散l䄌灰倮慬晴牯業圅湩㈳଀灁⹰敖獲潩楮ㄐ⸶⸰ㄱ㈱⸶〲㘲6䌉楬湥⹴摉ူۋċဃᒑ祆ᐬ丧劅斴疷ģက慄慴䄮瑣癩瑩呹条թ浢晭b䐛瑡⹡畄慲楴湯湉楍汬獩捥湯獤0貑䐎瑡⹡湉異呴灹づ鄀䐎瑡⹡瑓牡呴浩づ鄎鶬雑욵훉䐌瑡⹡畓捣獥び䐐瑡⹡敔敬敭牴䥹楤䔞捸汥䬮祥潢牡⹤摩䑫捯䅓䕖䅟瑬1䐑瑡⹡獕牥捁楴湯䑉0邑䐎癥捩⹥獏畂汩楤ㄅ㜷㌶က敄楶散伮噳牥楳湯ѩ〱〮฀癅湥⹴潃瑮慲瑣ᩩ晏楦散䰮来捡⹹潃浭湡",20069077,women,po.Gender,奉捷
10,"24 ||| Patients ||| 2.1 ||| Subjects were eligible for enrollment if they were ≥18 years of age with metabolic syndrome, had been on stable medications for 6 weeks prior to entry, had experienced an atherothrombotic vascular event or cardiovascular intervention ≥6 months earlier, and had an hs-CRP level between 2 mg/L and 10 mg/L at screening.",20069077,18 years of age,po.Age,奉捷
11,"24 ||| Patients ||| 2.1 ||| Subjects were eligible for enrollment if they were ≥18 years of age with metabolic syndrome, had been on stable medications for 6 weeks prior to entry, had experienced an atherothrombotic vascular event or cardiovascular intervention ≥6 months earlier, and had an hs-CRP level between 2 mg/L and 10 mg/L at screening.",20069077,with metabolic syndrome,po.Disease,奉捷
12,"24 ||| Patients ||| 2.1 ||| Subjects were eligible for enrollment if they were ≥18 years of age with metabolic syndrome, had been on stable medications for 6 weeks prior to entry, had experienced an atherothrombotic vascular event or cardiovascular interv",20069077,stable medications for 6 weeks,po.MedHistory,奉捷
13,"24 ||| Patients ||| 2.1 ||| Subjects were eligible for enrollment if they were ≥18 years of age with metabolic syndrome, had been on stable medications for 6 weeks prior to entry, had experienced an atherothrombotic vascular event or cardiovascular interv",20069077,had experienced an atherothrombotic vascular event,po.Disease,奉捷
14,"24 ||| Patients ||| 2.1 ||| Subjects were eligible for enrollment if they were ≥18 years of age with metabolic syndrome, had been on stable medications for 6 weeks prior to entry, had experienced an atherothrombotic vascular event or cardiovascular interv",20069077,cardiovascular intervention ≥6 months earlier,po.Disease,奉捷
15,"24 ||| Patients ||| 2.1 ||| Subjects were eligible for enrollment if they were ≥18 years of age with metabolic syndrome, had been on stable medications for 6 weeks prior to entry, had experienced an atherothrombotic vascular event or cardiovascular interv",20069077,had an hs-CRP level between 2 mg/L and 10 mg/L ,po.Disease,奉捷
16,"1 |||  ||| 0.1 ||| Metabolic syndrome is associated with intravascular inflammation, as determined by increased levels of inflammatory biomarkers and an increased risk of ischemic atherothrom-botic events.",20069077,Metabolic syndrome,pr.Disease,奉捷
17,3 |||  ||| 0.3 ||| Patients who had metabolic syndrome were randomized to receive clopidogrel 75 mg/ day plus aspirin 81 mg/day (n=89) or placebo plus aspirin 81 mg/day (n=92) for 9 weeks to assess the efficacy of each treatment in suppression of inflammatory markers.,20069077,had metabolic syndrome,po.Disease,奉捷
18,3 |||  ||| 0.3 ||| Patients who had metabolic syndrome were randomized to receive clopidogrel 75 mg/ day plus aspirin 81 mg/day (n=89) or placebo plus aspirin 81 mg/day (n=92) for 9 weeks to assess the efficacy of each treatment in suppression of inflammatory markers.,20069077,receive clopidogrel 75 mg/ day,i.Procedure,奉捷
19,3 |||  ||| 0.3 ||| Patients who had metabolic syndrome were randomized to receive clopidogrel 75 mg/ day plus aspirin 81 mg/day (n=89) or placebo plus aspirin 81 mg/day (n=92) for 9 weeks to assess the efficacy of each treatment in suppression of inflamma⊐᪇⊐क़᪈⊐ෘ᪈,20069077,aspirin 81 mg/day,i.Procedure,奉捷
20,3 |||  ||| 0.3 ||| Patients who had metabolic syndrome were randomized to receive clopidogrel 75 mg/ day plus aspirin 81 mg/day (n=89) or placebo plus aspirin 81 mg/day (n=92) for 9 weeks to assess the efficacy of each treatment in suppression of inflamma⊐᪇⊐क़᪈⊐ෘ᪈,20069077,placebo plus aspirin 81 mg/day,i.Procedure,奉捷
21,"75 ||| Patients ||| 2.52 ||| Clopidogrel and Inflammatory Markers in Metabolic Syndrome population were -151 pg/mL (95% CI, -251.1 to -34.92 pg/mL) for the clopidogrel plus aspirin group and -33.8 pg/mL (95% CI, 185 to 120.4 pg/mL) for the placebo plus aspirin group (Table II,  Fig.",20069077, the placebo plus aspirin group ,i.Procedure,奉捷
22,"30 ||| Patients ||| 2.7 ||| At Week 0, consenting, eligible patients were randomly assigned to receive blinded treatment with clopidogrel 75 mg/day plus aspirin 81 mg/day or placebo plus aspirin 81 mg/day.",20069077,receive blinded treatment with clopidogrel 75 mg/day,i.Procedure,奉捷
23,"30 ||| Patients ||| 2.7 ||| At Week 0, consenting, eligible patients were randomly assigned to receive blinded treatment with clopidogrel 75 mg/day plus aspirin 81 mg/day or placebo plus aspirin 81 mg/day.",20069077,plus aspirin 81 mg/day,i.Procedure,奉捷
24,"30 ||| Patients ||| 2.7 ||| At Week 0, consenting, eligible patients were randomly assigned to receive blinded treatment with clopidogrel 75 mg/day plus aspirin 81 mg/day or placebo plus aspirin 81 mg/day.",20069077,placebo plus aspirin 81 mg/day,i.Procedure,奉捷
25,"89 ||| Patients ||| 2.66 ||| Minor adverse events that were observed only in the clopidogrel plus aspirin group included immune hypersensitivity, seasonal allergy, hematuria, and renal failure.",20069077,immune hypersensitivity,i.SS,奉捷
26,"89 ||| Patients ||| 2.66 ||| Minor adverse events that were observed only in the clopidogrel plus aspirin group included immune hypersensitivity, seasonal allergy, hematuria, and renal failure.",20069077,renal failure,i.SS,奉捷
27,"89 ||| Patients ||| 2.66 ||| Minor adverse events that were observed only in the clopidogrel plus aspirin group included immune hypersensitivity, seasonal allergy, hematuria, and renal failure.",20069077, seasonal allergy,i.SS,奉捷
28,"89 ||| Patients ||| 2.66 ||| Minor adverse events that were observed only in the clopidogrel plus aspirin group included immune hypersensitivity, seasonal allergy, hematuria, and renal failure.",20069077,hematuria,i.SS,奉捷
29,"90 ||| Patients ||| 2.67 ||| The adverse events that were observed only in the placebo plus aspirin group included peripheral edema, cardiac palpitations, dyslipidemia, and spinal stenosis.",20069077,peripheral edema,i.SS,奉捷
30,"90 ||| Patients ||| 2.67 ||| The adverse events that were observed only in the placebo plus aspirin group included peripheral edema, cardiac palpitations, dyslipidemia, and spinal stenosis.",20069077,cardiac palpitations,i.SS,奉捷
31,"90 ||| Patients ||| 2.67 ||| The adverse events that were observed only in the placebo plus aspirin group included peripheral edema, cardiac palpitations, dyslipidemia, and spinal stenosis.",20069077,dyslipidemia,i.SS,奉捷
32,"90 ||| Patients ||| 2.67 ||| The adverse events that were observed only in the placebo plus aspirin group included peripheral edema, cardiac palpitations, dyslipidemia, and spinal stenosis.",20069077,spinal stenosis,i.SS,奉捷
33,104 ||| Discussion ||| 3.10 ||| Previous evidence indicates that the effects of clopidogrel on some inflammatory markers are more pronounced in patients who have elevated baseline levels of these biomarkers.,20069077,some inflammatory markers are more pronounced,o.Treatment,奉捷
34,117 ||| Discussion ||| 3.23 ||| This pilot study confirms previous reports that treatment with clopidogrel reduces levels of CD40 ligand and suggests an influence on the expression of P-selectin in patients with atherothrombosis.,20069077,reduces levels of,o.Treatment,奉捷
